Clinical Edge Journal Scan

Antiplatelet therapy may decrease HCC incidence and improve post-treatment outcomes


Key clinical point: Antiplatelet therapy (APT) reduces the risk for hepatocellular carcinoma (HCC) incidence by 40% and for all-cause mortality by 50% in patients with HCC treated with curative or palliative strategies.

Major finding: APT was associated with a significant reduction in the risk for HCC incidence (odds ratio [OR] 0.63; P < .0001) and post-treatment mortality (OR 0.54; P = .006).

Study details: This study was a meta-analysis of 15 studies that investigated the impact of APT on HCC incidence in 2,685,009 individuals and five studies that investigated post-treatment mortality in 3281 patients with HCC, both with respect to APT use.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Lai Q et al and the Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group. The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma. Eur J Clin Invest. 2022:e13870 (Sep 8). Doi: 10.1111/eci.13870

Recommended Reading

TARE vs TACE prolongs time to progression in HCC but not overall survival
Federal Practitioner
Commentary: Evaluating HCC Treatments, October 2022
Federal Practitioner
Unresectable HCC: Atezolizumab plus bevacizumab proves its worth in the clinic
Federal Practitioner
Ramucirumab effective in patients with advanced HCC and AFP ≥400 ng/mL after non-sorafenib therapies
Federal Practitioner
Hepatectomy recommended for select patients with multiple HCC
Federal Practitioner